SP-0231 IAEA TRS 398: Update for modern radiotherapy

2021 ◽  
Vol 161 ◽  
pp. S159
Author(s):  
H. Palmans
Keyword(s):  
1977 ◽  
Vol 113 (5) ◽  
pp. 650-654 ◽  
Author(s):  
A. T. Farina
Keyword(s):  

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3384
Author(s):  
Martin Leu ◽  
Christoph Patzer ◽  
Manuel Guhlich ◽  
Jacqueline Possiel ◽  
Yiannis Pilavakis ◽  
...  

Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved.


2014 ◽  
Vol 111 ◽  
pp. S29-S30
Author(s):  
L. Murray ◽  
C.M. Thompson ◽  
J. Lilley ◽  
K. Franks ◽  
D. Sebag-Montefiore ◽  
...  

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Masaki Kimura ◽  
Hui Yan ◽  
Zahid Rabbani ◽  
Takefumi Satoh ◽  
Shiro Baba ◽  
...  

2017 ◽  
Vol 35 (15) ◽  
pp. 1641-1649 ◽  
Author(s):  
Carolyn Taylor ◽  
Candace Correa ◽  
Frances K. Duane ◽  
Marianne C. Aznar ◽  
Stewart J. Anderson ◽  
...  

Purpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer radiotherapy versus no radiotherapy in 75 trials yielded rate ratios (RRs) for second primary cancers and cause-specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality. Smoking status was unavailable. Third, the lung or heart ERRs per Gy in the trials and the 2010 to 2015 doses were combined and applied to current smoker and nonsmoker lung cancer and cardiac mortality rates in population-based data. Results Average doses from 647 regimens published during 2010 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart. The median year of irradiation was 2010 (interquartile range [IQR], 2008 to 2011). Meta-analyses yielded lung cancer incidence ≥ 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis of 134 cancers, indicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose. For cardiac mortality, RR was 1.30 (95% CI, 1.15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths. Detailed analyses indicated 0.04 (95% CI, 0.02 to 0.06) ERR per Gy whole-heart dose. Estimated absolute risks from modern radiotherapy were as follows: lung cancer, approximately 4% for long-term continuing smokers and 0.3% for nonsmokers; and cardiac mortality, approximately 1% for smokers and 0.3% for nonsmokers. Conclusion For long-term smokers, the absolute risks of modern radiotherapy may outweigh the benefits, yet for most nonsmokers (and ex-smokers), the benefits of radiotherapy far outweigh the risks. Hence, smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy risk.


Sign in / Sign up

Export Citation Format

Share Document